Skip to Main Navigation Skip to Page Content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

beta-Thioguanidine deoxyriboside: Target Organs and Levels of Evidence for TR-057

Bioassay of ß-TGdR for Possible Carcinogenicity (CASRN 789-61-7)

Chemical (Study Title) CASRN	Peer Review Date	Route/Exposure Levels	Study Laboratory
beta-Thioguanidine deoxyriboside 789-61-7	02/18/1978	Intraperitoneal Injection R: 0,3.5,7, M: 0,1,4 MG/KG/35 PER GROUP	Southern Research Institute

Levels of Evidence

Male Rats: Equivocal

Type	Organ/Tissue (Lesion)
Neoplastic Lesions	Zymbal Gland: (CARCINOMA)

Female Rats: Positive

Type	Organ/Tissue (Lesion)
Neoplastic Lesions	Zymbal Gland: (CARCINOMA)

beta-Thioguanidine deoxyriboside: Target Organs and Levels of Evidence for TR-057

Bioassay of ß-TGdR for Possible Carcinogenicity (CASRN 789-61-7)

Levels of Evidence

Male Rats: Equivocal

Female Rats: Positive

Male Mice: Inadequate Study

Female Mice: Inadequate Study